抗血栓预处理增加原发性脑出血极早期死亡率
这项前瞻性观察研究分析了529例原发性脑出血患者,按抗血栓预处理分为无、抗血小板(AP)或维生素K拮抗剂(VKA)三组。结果显示AP和VKA预处理均显著增加24小时死亡风险,且该效应驱动了3个月死亡率的升高,同时降低功能独立比例。
要点
- AP或VKA预处理者脑出血后24小时死亡率显著高于未预处理者。
- VKA预处理对极早期死亡的调整OR为4.24,AP预处理为2.55。
- 抗血栓预处理对24小时至3个月期间的死亡影响不显著。
核心结论
- VKA或AP预防性治疗的患者脑出血后极早期死亡率高,两者均为极早期死亡的预测因素。
- 抗血栓药物对3个月死亡率的影响主要通过其强烈的极早期死亡效应实现。
研究设计与样本
- 前瞻性观察研究,纳入529例原发性脑出血患者。
- 按抗血栓预处理分为无预处理、AP预处理和VKA预处理三组进行分析。
主要发现
- 236例(44.6%)患者接受预处理,其中AP 147例(27.8%),VKA 89例(16.8%)。
- 极早期死亡总体为13.4%,AP组19.0%,VKA组27.0%,无预处理组6.5%,p < 0.0001。
- 3个月死亡率总体40.8%,AP组49.7%,VKA组58.4%,无预处理组31.1%,p < 0.0001。
- 调整后极早期死亡OR:AP组2.55(p = 0.004),VKA组4.24(p < 0.0001);3个月死亡OR:AP组1.56(p = 0.046),VKA组2.34(p = 0.01)。
- 3个月功能独立比例总体28.5%,AP组22.4%,VKA组15.7%,无预处理组35.5%,p < 0.0001。
关键数值与推荐
- 极早期死亡定义为24小时内死亡。
- 功能独立评估于3个月随访时进行。
临床怎么用
- 对计划长期使用VKA或AP的患者,应关注脑出血后极早期死亡风险。
- 启动慢性抗血栓治疗时需权衡安全性,不仅限于VKA,也包括AP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the effect of previous antiplatelet (AP) and vitamin K antagonist (VKA) treatments on outcome in patients with primary intracerebral hemorrhage (ICH). METHODS: In this prospective observational study, we analyzed 529 patients according to antithrombotic pretreatment: none, AP, or VKA. Very-early (24-hour) death, 3-month mortality, and functional independence were analyzed. RESULTS: Of 236 (44.6%) pretreated patients, 147 (27.8%) patients were taking AP and 89 (16.8%) VKA. Very-early death was observed in 13.4% and was increased in pretreated patients: 19.0% for AP and 27.0% for VKA treatment, compared to 6.5% in non-pretreated patients, p < 0.0001. Three-month mortality was 40.8% overall (49.7% for AP pretreated, 58.4% for VKA pretreated, and 31.1% for non-pretreated patients, p < 0.0001). The adjusted odds of very-early and 3-month mortality were 2.55 (p = 0.004) and 1.56 (p = 0.046) for AP-pretreated patients and 4.24 (p < 0.0001) and 2.34 (p = 0.01) for VKA-pretreated patients, respectively, compared with non-pretreated patients. The effect of antithrombotic pretreatment on mortality from 24 hours to 3 months was nonsignificant. At 3-month follow-up, 28.5% of patients remained functionally independent: 22.4% of AP-pretreated, 15.7% of VKA-pretreated, and 35.5% of non-pretreated patients (p < 0.0001). CONCLUSIONS: A high percentage of patients with ICH preventively treated with VKA or AP died during the first 24 hours after admission. Both treatments were predictors of very-early mortality. The final effect of antithrombotics on 3-month mortality remains significant through its strong effect on very-early mortality. Safety concerns about starting chronic antithrombotic treatment should be considered not only when VKA treatment is planned but also for AP treatment.
引用
- Roquer J, Vivanco Hidalgo RM, Ois A, et al. Antithrombotic pretreatment increases very-early mortality in primary intracerebral hemorrhage. Neurology. 2017. PMID: 28148636. doi:10.1212/WNL.0000000000003659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。